Holen Sie sich die Stockscreener-App
87.48
1.38%
-1.22
Handel nachbörslich:
87.49
0.010
+0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$88.70
Offen:
$87.9
24-Stunden-Volumen:
1.02M
Relative Volume:
0.60
Marktkapitalisierung:
$44.00B
Einnahmen:
$9.93B
Nettoeinkommen (Verlust:
$1.12B
KGV:
38.88
EPS:
2.25
Netto-Cashflow:
$1.58B
1W Leistung:
-0.34%
1M Leistung:
-1.24%
6M Leistung:
+4.88%
1J Leistung:
-3.38%
1-Tages-Spanne:
$87.38
$88.26
1-Wochen-Bereich:
$86.01
$89.46
52-Wochen-Spanne:
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
87.48 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
ISRG
Intuitive Surgical Inc
|
512.06 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
175.97 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
254.40 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
227.18 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions - Eyes On Eyecare
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients - Ophthalmology Times
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target - Investing.com
Alcon sees the light with Lumithera buy for dry AMD - BioWorld MedTech
Alcon Stock Gains Following UNITY VCS' Approval in Canada - TradingView
Alcon to acquire LumiThera for dry AMD treatment device - MSN
Alcon to purchase LumiThera - Eyes On Eyecare
Alcon's Unity VCS Gets Health Canada Approval - Nasdaq
Alcon snaps up LumiThera for light-based AMD treatment - Optics.org
Alcon Gets Health Canada Approval on Unity Vitreoretinal Cataract System - MarketScreener
Alcon : Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - MarketScreener
Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval - Business Wire
Alcon To Acquire LumiThera - citybiz
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Ophthalmology Times
Alcon to acquire LumiThera and its dry AMD light therapy device - Investing.com
Alcon To Acquire LumiThera And Its Photobiomodulation Device - Nasdaq
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) - Business Wire
Alcon Inc (ALC) Announces Approval of Clareon PanOptix Pro Intraocular Lens - Insider Monkey
Do Options Traders Know Something About Alcon Stock We Don't? - MSN
Stifel reiterates Buy rating on Alcon stock amid IOL market dynamics - Investing.com
Is it Apt to Retain Alcon Stock in Your Portfolio for Now? - Nasdaq
Alcon Canada Earns Global Recognition as a Top Employer - Yahoo Finance
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL - Yahoo Finance
Alcon and Merit Medical: Creating Regulatory and Quality Business Value with AI - Veeva
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st
Alcon Gets First FDA Approval Since Novartis Spinoff - Orange County Business Journal
Alcon’s Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold' (NYSE:ALC) - Seeking Alpha
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN
Phacoemulsification Devices Market Is Booming Worldwide - openPR.com
Alcon: Achieving UDI Compliance with Veeva RIM - Veeva
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stoc - GuruFocus
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stock News - GuruFocus
Citi more constructive on EU MedTech: Upgrades Demant; Alcon top pick - Investing.com Canada
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - MSN
BofA Securities lowers Alcon stock price target after Q1 results By Investing.com - Investing.com South Africa
BofA Securities lowers Alcon stock price target after Q1 results - Investing.com Australia
Refractive Surgery Market Is Booming So Rapidly 2025-2032 - openPR.com
Alcon up 4% as FDA approves Tryptyr drops for dry eye - MSN
Citi maintains Buy on Alcon, price target CHF99 after FDA nod - Investing.com Nigeria
Alcon gains FDA approval of Tryptyr in DED - The Pharma Letter
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch By Investing.com - Investing.com Canada
Citi maintains Buy on Alcon, price target CHF99 after FDA nod By Investing.com - Investing.com South Africa
FDA Approves Alcon’s Tryptyr for Dry Eye Disease - Managed Healthcare Executive
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
Alcon Stock Rises Following the FDA Approval of TRYPTYR - MSN
US FDA approves Alcon's new dry-eye drug - Reuters
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease - Ophthalmology Times
Alcon receives FDA approval for Tryptyr to treat dry eye disease - World Pharmaceutical Frontiers
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com
Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target - TipRanks
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):